Xarelto and Tafamidis: Another Case of Less is More

A pair of advisory committee reviews at the start of June offered an interesting contrast: a big study with small flaws versus a small study with big flaws. At least at the committee level, the small study fared much better. Is this another vote against mega R&D investments?